Idiopathic Pulmonary Fibrosis

The current survival rate of Idiopathic Pulmonary Fibrosis (IPF) is as low as some of the most devastating cancers. Thanks to research, recent advances in new treatments are helping to slow the progression of the disease in some cases.

While this is promising, more research is desperately needed to better understand this complex disease so we can drive further progress of treatments, improve the late rate of diagnosis, support psychological management and search for a cure.

“As a result of being diagnosed by coincidence, and at such an early stage, I was able to start taking one of the new drugs, which aims to slow the progression of IPF by up to 50 per cent. This was the first time I had really experienced any encouragement or hope since I was diagnosed,”

Bill, lives with IPF

Lung Foundation Australia is committed to driving dedicated research that will help improve the health outcomes and quality of life for those affected by IPF. Our research program includes a world renowned IPF registry, clinical trials group and a suite of IPF research awards and grants.

Research awards and grants

Our IPF research awards and grants encourage early career and senior researchers and clinicians to undertake dedicated research into the diagnosis, treatment and management of IPF. Find out more about our research awards program and how to apply for funding.

Centre for Research Excellence – Pulmonary Fibrosis

Lung Foundation Australia is proud to be a founding partner of the Centre for Research Excellence – Pulmonary Fibrosis (CRE-PF), a comprehensive and integrated clinical research program that aims to change the approach to Pulmonary Fibrosis (PF) care and treatment in Australia.